A drug is approved to treat osteoporosis in older women protects them against breast cancer. It is just as well as the standard breast cancer prevention drug tamoxifen. It has fewer serious side effects also. According to the study, Raloxifene with Tamoxifen both reduced invasive breast cancers by 50 percent.
But women taking raloxifene had fewer uterine cancers, fewer blood clots in the legs and lungs than those taking tamoxifen. Raloxifene did not increase the risk of cataracts or menopausal symptoms as tamoxifen does.
The study did not include premenopausal women. There is no data showing whether raloxifene is safe for them or not.